This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than ...

Nimacimab is a first-in-class humanized monoclonal antibody that acts as a negative allosteric modulator to inhibit CB1 signaling in the periphery. Inhibition of CB1 has shown anti-fibrotic, ...

Skye Bioscience (NASDAQ:SKYE) is a micro-cap pharmaceutical company that is striving to become the next big thing in the weight loss drug space. The massive success of glucagon-like peptide-1 (GLP-1) ...

SAN DIEGO, CA, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat ...

Skye Bioscience (NASDAQ:SKYE) is set to give its latest quarterly earnings report on Tuesday, 2026-03-10. Here's what investors need to know before the announcement. Analysts estimate that Skye ...

Skye Bioscience Inc (NASDAQ:SKYE) has established a potential path for namasimab alongside existing incretin therapies, showing additive weight loss and favorable tolerability. The company has ...

We recently compiled a list of 7 Best Russell 2000 Stocks to Buy According to Analysts. In this article, we will look at where Skye Bioscience, Inc. (NASDAQ:SKYE) ranks among the best Russell 2000 ...

Detailed price information for Skye Bioscience Inc (SKYE-Q) from The Globe and Mail including charting and trades.

) has been revised to $7.87 / share. This is a decrease of 11.48% from the prior estimate of $8.89 dated April 25, 2026. The price target is an average of many targets provided by analysts. The latest ...

Detailed price information for Skye Bioscience Inc (SKYE-Q) from The Globe and Mail including charting and trades.

Nimacimab is a potential first-in-class, peripherally-restricted monoclonal antibody inhibitor of the CB1 receptor. Unlike previous CB1-targeting drugs, nimacimab is designed to avoid central nervous ...